natgillin/translations-raw huggingface dataset:
Forud for påføring af EVICEL skal sårets overfladeareal tørres ved brug af standardteknikker (f.eks. intermitterende applikation af kompresser, vatpinde, tamponer, brug af sugeanordninger).
Prior to applying EVICEL the surface area of the wound needs to be dried by standard techniques (e.g., intermittent application of compresses, swabs, use of suction devices).
Forud for udlevering af ordinationsvejledningen i hver enkelt medlemsstat skal indehaveren af markedsføringstilladelsen og den relevante nationale myndighed være blevet enige om indholdet og formatet af informationsmaterialet samt en kommunikationsplan.
Prior to distribution of the prescriber guide in each Member State, the MAH agreed the content and format of the educational material, together with a communication plan, with the national competent authority.
Forud for udlevering af ordinationsvejledningen i hver enkelt medlemsstat skal indehaveren af markedsføringstilladelsen og den relevente nationale myndighed være blevet enige om indholdet og formatet af informationsmaterialet samt en kommunikationsplan.
Prior to distribution of the prescriber guide in each Member State, the MAH agreed the content and format of the educational material, together with a communication plan, with the national competent authority.
Forud for udleveringen af lægemidlet til en bestemt sundhedsinstitution skal indehaveren af markedsføringstilladelsen sikre, at følgende personer modtager uddannelse som anført i uddannelsesprogrammet, der er beskrevet i risikostyringsplanen: Alle kirurger og andet sundhedspersonale, som er inddraget i håndteringen og administrationen af ChondroCelect og komponenterne heri, samt de personer, som er inddraget i opfølgningen af de patienter, der er blevet behandlet med ChondroCelect i sundhedsinstitutionen.
The Marketing Authorisation Holder (MAH) shall ensure, prior to the distribution of the product to a particular healthcare establishment, that all surgeons and other healthcare professionals involved in the handling and administration of ChondroCelect or its components, as well as those involved in follow- up of patients treated with ChondroCelect in the healthcare establishment, receive training as per the educational programme described in the risk management plan.
Forud planlagte interrim-analyser af begge studier viste, at lenalidomid/dexamethason statistisk var væsentligt bedre (p<0,00001) end dexamethason alene til at nå det primære endepunkt, TTP (median opfølgningsvarighed på 98,0 uger).
Pre-planned interim analyses of both studies showed that lenalidomide/dexamethasone was statistically significantly superior (p < 0.00001) to dexamethasone alone for the primary efficacy endpoint, TTP (median follow-up duration of 98.0 weeks).
Forud specificeret foreløbig analyse
Pre-specified interim analysis
Foruden cysteamin kan behandlingen bestå i et eller flere kosttilskud som erstatning for vigtige elektrolytter, der tabes gennem nyrerne.
Your medical treatment may include, in addition to cysteamine, one or more supplements to replace important electrolytes lost through the kidneys.
Foruden de nedenstående bivirkninger kan følgende også forekomme ved brugen af Temodal som pulver til opløsning til infusion, opløsning: smerte, irritation, kløe, varme, hævelse eller rødme på injektionsstedet; også blå mærker (hæmatoma).
In addition to the side effects listed below, the following may also occur with the use of Temodal powder for solution for infusion: pain, irritation, itching, warmth, swelling or redness at the injection site; also bruising (haematoma).
Foruden disse tre komponenter vil der også være behov for 0,9 % (vægt/vol.) natriumchloridopløsning til injektion til rekonstitution af doxorubicin HCl.
In addition to these three components, 0.9% (w/v) sodium chloride solution for injection will also be required for the reconstitution of the doxorubicin HCl.
Foruden Glybera vil du også få immundæmpende lægemidler (se afsnit 3 “Sådan skal du bruge Glybera”).
In addition to being given Glybera, you will be given other medicines called immunosuppressants (see section 3 ‘How Glybera is used’).
Foruden ovenstående kriterier skal der anvendes lægelig dømmekraft ved evaluering af patientens kardiovaskulære funktioner.
In addition to the above criteria, clinician judgement must be exercised in the evaluation of the patient’s cardiovascular functions.
Forudgående behandling med andre anti-inflammatoriske midler kan give yderligere eller kraftigere bivirkninger, og man skal derfor have en behandlingsfri periode med sådanne lægemidler før behandling med Cimalgex påbegyndes.
Pre- treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before the commencement of treatment with Cimalgex.
Forudgående behandling med andre anti-inflammatoriske midler kan give yderligere eller kraftigere bivirkninger, og man skal derfor observere en behandlingsfri periode med sådanne lægemidler før behandling med Cimalgex påbegyndes.
Pre- treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before starting treatment with Cimalgex.
Forudgående behandling med andre antiinflammatoriske substanser end Metacam 2 mg/ml injektionsvæske, opløsning til katte på en enkelt dosis på 0,2 mg/kg kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en periode uden behandling med disse veterinære lægemidler på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances other than Metacam 2 mg/ml solution for injection for cats at a single dose of 0.2 mg/kg may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med andre antiinflammatoriske substanser end Metacam 2 mg/ml injektionsvæske, opløsning til katte på en enkelt dosis på 0,2 mg/kg kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en periode uden behandling med sådanne veterinære lægemidler på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances other than Metacam 2 mg/ml solution for injection for cats at a single dose of 0.2 mg/kg may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med ant-iinflammatoriske stoffer kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode med sådanne veterinærlægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med anti-inflammatoriske stoffer kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode med sådanne veterinærlægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med anti-inflammatoriske stoffer kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode med sådanne veterinærlægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such medicines should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med anti-inflammatoriske stoffer kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der ikke behandles med sådanne veterinære lægemidler i en periode på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode med sådanne veterinærlægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode med sådanne veterinærlægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such medicines should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode uden disse veterinære lægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment with Loxicom.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en behandlingsfri periode uden disse veterinære lægemidler på mindst 24 timer, inden behandling påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en periode uden behandling med disse veterinære lægemidler på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en periode uden behandling med sådanne veterinære lægemidler på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Forudgående behandling med antiinflammatoriske substanser kan resultere i yderligere eller forstærkede bivirkninger, og derfor bør der indlægges en periode uden behandling med sådanne veterinærlægemidler på mindst 24 timer, inden behandlingen påbegyndes.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Forudgående eksponering for cytotoksiske midler
Prior exposure to cytotoxic agents
forudgås normalt
liver injury
Forudsat at patienten ikke får uacceptable bivirkninger, skal dosis titreres indtil den maksimale terapeutiske effekt.
Providing patients do not experience intolerable undesirable effects, the dosage should be titrated to achieve a maximal therapeutic effect.
Forudsat at raltegravir er metaboliseret primært via UGT1A1, bør der udvises forsigtighed, når ISENTRESS administreres sammen med potente inducere af UGT1A1 (f.eks. rifampicin).
Given that raltegravir is metabolised primarily via UGT1A1, caution should be used when co-administering ISENTRESS with strong inducers of UGT1A1 (e.g., rifampicin).
Forudsat at raltegravir primært metaboliseres via UGT1A1, bør der udvises forsigtighed, når ISENTRESS administreres sammen med potente inducere af UGT1A1 (f.eks. rifampicin).
Given that raltegravir is metabolised primarily via UGT1A1, caution should be used when co-administering ISENTRESS with strong inducers of UGT1A1 (e.g., rifampicin).
Forudsigelighed af respons og non-respons ved hcv/hiv co-infektion  Tidlig virologisk respons i Uge 12, defineret som et 2 log viralt fald i load eller ikke-detekterbare niveauer af hcv-RNA, har vist sig at være forudsigeligt for et vedvarende respons.
Predictability of response and non-response in HCV/HIV co-infection - Early virological response by week 12, defined as a 2 log viral load decrease or undetectable levels of HCV-RNA, has been shown to be predictive for sustained response.
Forudsigelighed af respons og non-respons ved Pegasys og ribavirin to-stofsbehandling – behandlingserfarne patienter
Predictability of response and non-response with Pegasys and ribavirin dual therapy – treatment- experienced patients
Forudsigelighed af respons og non-respons ved Pegasys og ribavirin to-stofsbehandling – behandlingsnaive patienter
Predictability of response and non-response with Pegasys and ribavirin dual therapy – treatment- naïve patients
Forudsigelighed med hensyn til vedvarende virologisk respons hos naive patienter
Predictability of sustained virological response in naïve patients
Forveksling af insuliner
Insulin Mix-ups
Forventede bivirkninger
Expected adverse effects
Forventede bivirkninger
Expected adverse reactions
Forventede gennemsnitlige tocilizumab-eksponeringsparametre var ens i de to vægtgrupper.
Mean predicted tocilizumab exposure parameters were similar between the two body weight groups.
Forventelige bivirkninger i titreringsfasen og håndtering heraf.
Expectations and management of adverse events during the titration phase;
forventes at blive mindsket af
lopinavir/ritonavir, and is
forventes at give en substantiel reduktion af
John's Wort is expected to substantially
forventes at give en substantiel reduktion af
St. John's Wort is expected to
forventes at give et væsentlig
expected to substantially decrease
forventes at nedsætte
decrease cobicistat plasma
forventes at øge plasmakoncentrationen af
expected to increase the plasma
forventes at øge plasmakoncentrationen af
expected to increase these antiarrhythmic
forventes at øge plasmakoncentrationen af
expected to increase these antineoplastic
forventes at øge plasmakoncentrationen af
expected to increase these antipsychotic
forventes at øge plasmakoncentrationen af
expected to increase these β-blocker
forventes ingen effekt.
measured, no effect expected.
forventes ingen interaktion.
measured, no interaction expected.
forventes ingen interaktion.
no interaction expected.
Forventes på grund af antiepileptikas induktion af CYP3A4:
Expected due to CYP3A4 induction by the anticonvulsant:
Forventes på grund af antimykotikas hæmning af CYP3A4:
Expected due to CYP3A4 inhibition by the antifungal:
Forventes på grund af atazanavirs/cobicistats hæmning af CYP3A4:
Expected due to CYP3A4 inhibition by atazanavir/cobicistat:
Forventes på grund af daclatasvirs hæmning af OATP 1B1 og/eller BCRP:
Expected due to inhibition of OATP 1B1 and/or BCRP by daclatasvir:
Forventes på grund perikons induktion af CYP3A4:
Expected due to CYP3A4 induction by St. John’s wort:
Forventet FEV1-procent Baseline-gennemsnit (SD)
FEV1 Percent predicted Baseline mean (SD)
Forventet gennemsnitlig ( SD) AUC4uger, Cmax og Cmin for tocilizumab var henholdsvis 23.200 ± 6.100 µgt/ml, 175  32 µg/ml og 2,35  3,59 µg/ml.
The predicted mean ( SD) AUC4weeks, Cmax and Cmin of tocilizumab were 23200 ± 6100 µghr/mL, 175  32 µg/mL and 2.35  3.59 µg/mL, respectively.
Forventet gennemsnitlig ( SD) AUC4uger, Cmax og Cmin for tocilizumab var henholdsvis 29.500 ± 8.660 µgt/ml, 182  37 µg/ml og 7,49  8,20 µg/ml.
The predicted mean ( SD) AUC4weeks, Cmax and Cmin of tocilizumab were 29500 ± 8660 µghr/mL, 182  37 µg/mL and 7.49  8.20 µg/mL, respectively.
Forventet median Cmax (q2m) µg/ml
Predicted median Cmax (q2m) µg/mL
Forventet median Cmax (q3m) µg/mL
Predicted median Cmax (q3m) µg/mL
forventet pga. induktion
expected due to induction
Forventet:
Expected
Forventet:
Expected in CYP2C19 Extensive
Forvirret adfærd
Appearing and acting confused
forvirring
confusion,
Forvirring
Gastrointestinal disorders
forvirring betændelse i venerne og dannelse af blodpropper i venerne, hvilket kan føre til blokering af blodtilførslen til lungerne og give vejrtrækningsbesvær, brystsmerter og hjertebanken.
confusion; inflammation of the veins and formation of blood clots in the veins which could lead to blockage of blood flow to your lungs causing difficulty breathing, chest pain and palpitations.
Forvirring eller desorientering
Confusion or feeling disorientated
Forvirring eller hallucinationer
Confusion or hallucinations Taste disorders
forvirring eller uro
feeling confused or agitated
forvirring eller ændret opmærksomhed og reaktionsevne
Confusion or change in how alert you are,
forvirring påvirket bevidsthedstilstand, f.eks koma
confusion, depressed level of consciousness (e.g. coma).
forvirring påvirket bevidsthedstilstand, f.eks. koma.
confusion, depressed level of consciousness (e.g. coma).
forvirring,
confusion,
Forvirring, angst, depression, svimmelhed, søvnbesvær (insomni)
Confusion, anxiety, depression, dizziness, difficulty sleeping (insomnia)
forvirring, desorientering,
confusion, disorientation
forvirring, desorientering, hukommelsestab, ændret humør, mangel på energi
confusion, disorientation, memory loss, disturbed mood, lack of energy
forvirring, desorienteringd, agitationd
Eye disorders
forvirring, hallucinationerbevægelsesforstyrrelser og ufrivillige bevægelser (dystoni) overdrevne drømme
movement disorder with involuntary muscle spasms or malpositions (dystonia), dreaming excessive.
Forvirring, hukommelsestab eller koncentrationsbesvær
Confusion, memory loss or problems thinking
forvirring, nedtrykthed, selvmordstanker eller aggressiv opførsel, selvmordforsøg, tanker om at true andre på livet
confusion, feeling depressed; suicidal thoughts or aggressive behaviour, attempt suicide, thoughts about threatening the life of others
forvirring, nedtrykthed, selvmordstanker eller aggressiv opførsel, selvmordforsøg, tanker om at true andre på livet,
confusion, feeling depressed; suicidal thoughts or aggressive behaviour, attempt suicide, thoughts about threatening the life of others
forvirring, nedtrykthed, selvmordstanker eller aggressiv opførsel, selvmordforsøg, tanker om at true andre på livet,
confusion, feeling depressed; suicidal thoughts or aggressive behaviour, attempt suicide, thoughts about threatening the life of others,
forvirring, nedtrykthed, selvmordstanker eller aggressiv opførsel, selvmordsforsøg, tanker om at true andre på livet,
confusion, feeling depressed; suicidal thoughts or aggressive behaviour, attempt suicide, thoughts about threatening the life of others,
forvirring, panikanfald, depression, nedsat sexlyst,
confusional state, panic attacks, depressed mood, decreased libido
forvirring, panikanfald, deprimeret sindstilstand, nedsat seksualdrift
confusional state, panic attacks, depressed mood, decreased libido
forvirring, panikanfald, nedtrykt sindsstemning, nedsat sexlyst
confusional state, panic attacks, depressed mood, decreased libido
forvirring, synstab eller -forstyrrelser, blindhed, krampeanfald, hovedpiner
confusion, visual loss or disturbances, blindness, seizures, headaches
forvirring, synstab eller synsforstyrrelser, blindhed, krampeanfald, hovedpine
confusion, visual loss or disturbances, blindness, seizures, headaches
Forvirring, søvnforstyrrelser, nedsat libido
Confusion, sleep disorder, libido decreased
forvirring, træthed, muskelsammentrækninger og -kramper, hurtigt åndedræt (hypokloræmisk alkalose)
confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)
Forvirring.
Being confused.
Forvirring.
Confusion.
Forvirring.
Feeling confused
Forvirringam
Confusionam
Forvrænget sansefornemmelse på huden, f.eks. prikken, snurren eller kløe (paræstesi) hos børn
Abnormal sensation of the skin, such as pricking, tingling and itchiness (paresthesia) in children
Forvrænget sansefornemmelse, f.eks. prikken, snurren eller kløe (paræstesi) hos voksne
Abnormal sensation, such as pricking, tingling, or itchiness (paresthesia) in adults
Forvrænget smagssans (dysgeusia)
Distorted sense of taste (dysgeusia)
forvrænget syn
distorted vision
forvrængning**,
distortions**,
Forvæ rring af dermatomyositis-symptomer.
Worsening of symptoms of dermatomyositis.
Forvæ rring af en sygdom, der kaldes dermatomyositis (observeres som hududslæ t ledsaget af muskelsvaghed)
Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness).
Forværret
Deteriorated
forværret allergi
Allergy aggravated
Forværret astma
asthma aggravated
forværret depression,
depression aggravated,
forværret epilepsi (mulige hyppigere og/eller kraftigere anfald)
Worsening of epilepsy (possible more frequent and/or severe seizures)
forværret hypertension forværret albuminuri
worsening hypertension worsening albuminuria
forværret konfusion
confusion aggravated
Forværret leddegigt
worsening of rheumatoid arthritis
forværret nyrefunktion (defineres som en vedvarende [reproduceret over mindst 2 uger] 25 % reduktion i gensidig serum-kreatinin under behandling [fra afslutningen af titrering til sidste besøg, hvor lægemidlet blev taget])
worsening kidney function (defined as a persistent [reproduced over at least 2 weeks] 25% reduction in reciprocal serum creatinine during treatment [from end of titration to last on-drug visit])
Forværret reumatoid artritis
Rheumatoid arthritis aggravated
Forværret rygskævhed (skoliose) (på grund af hurtig vækst)
Worsened scoliosis (caused by rapid growth)
forværret ængstelse,
anxiety aggravated,
Forværring
Worsening
forværring af
exacerbation of
forværring af
exacerbation of diabetes